OBJECTIVES: To assess the budgetary impact of XELOX (combination regimen of Xeloda plus oxaliplatine) as a treatment option in colorectal cancer in Italy. METHODS: A matrix model was developed to estimate the budgetary impact of XELOX from the perspective of the health care purchaser in Italy in 2008. The analysis was performed for patients with colorectal cancer receiving 5-FU, FOLFOX-4 (or FOLFOX-6 or FOLFOX-6 modified), FOLFIRI, Xeloda (capecitabine), who are eligible for treatment with XELOX. Data sources used include published literature, official Italian price/tariff lists, and national population statistics. The analysis covers adjuvant therapy for colon cancer and 1st and 2nd line treatment in metastatic colorectal cancer (mCRC) over a 5-year time horizon. The perspective of the analysis was that of the NHS in Italy in 2008. RESULTS: The analysis shows that the total treatment costs decrease when XELOX is introduced as a treatment option in colorectal cancer. The introduction of XELOX leads to cost savings at the national level of €65 million over a period of 5 years, when the FOLFOX regimen consists of FOLFOX-4. The use of XELOX leads to additional costs of €154 million for XELOX, but these costs are offset by cost savings for the other regimens and especially FOLFOX (€171 million) and FOLFIRI (€26 million). For FOLFOX-6 and FOLFOX-6 modified the cost savings are respectively €52 and of €22 million. Sensitivity analyses confirmed the robustness of the outcome of the model. CONCLUSIONS: The use of XELOX leads to a positive impact on the national drug budget in terms of costs savings in patients with colorectal cancer.
Nuijten MC 1 , Giuliani G 2 , de Reydet de Vulpillières F 3 1 Erasmus University Rotterdam, Rotterdam, The Netherlands, 2 Roche S.p.A, Milano, Italy, 3 F. Hoffman-La Roche, Basel, Switzerland OBJECTIVES: To assess the budgetary impact of XELOX (combination regimen of Xeloda plus oxaliplatine) as a treatment option in colorectal cancer in Italy. METHODS: A matrix model was developed to estimate the budgetary impact of XELOX from the perspective of the health care purchaser in Italy in 2008. The analysis was performed for patients with colorectal cancer receiving 5-FU, , FOLFIRI, Xeloda (capecitabine) , who are eligible for treatment with XELOX. Data sources used include published literature, official Italian price/tariff lists, and national population statistics. The analysis covers adjuvant therapy for colon cancer and 1st and 2nd line treatment in metastatic colorectal cancer (mCRC) over a 5-year time horizon. The perspective of the analysis was that of the NHS in Italy in 2008. RESULTS: The analysis shows that the total treatment costs decrease when XELOX is introduced as a treatment option in colorectal cancer. The introduction of XELOX leads to cost savings at the national level of €65 million over a period of 5 years, when the FOLFOX regimen consists of FOLFOX-4. The use of XELOX leads to additional costs of €154 million for XELOX, but these costs are offset by cost savings for the other regimens and especially FOLFOX (€171 million) and FOLFIRI (€26 million). For FOLFOX-6 and FOLFOX-6 modified the cost savings are respectively €52 and of €22 million. Sensitivity analyses confirmed the robustness of the outcome of the model. CONCLUSIONS: The use of XELOX leads to a positive impact on the national drug budget in terms of costs savings in patients with colorectal cancer.
PCN13 BUDGET IMPACT ANALYSIS OF THE CONTINUATION OF DOCETAXEL REIMBURSEMENT IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER AND PALLIATIVE THERAPY OF METASTATIC BREAST CANCER IN POLAND
Walczak J 1 , Gebus E 1 , Lasota K 1 , Semeniuk A 1 , Malczak I 1 , Pawlik D 1 , Lis J 2 , Glasek M 2 , Nogas G 1 1 Arcana Institute, Cracow, Poland, 2 Sanofi-Aventis sp. z o.o, Warsaw, Poland OBJECTIVES: To estimate the impact on the budget of the Public Payer in Poland of the continuation of docetaxel reimbursement in the neoadjuvant therapy of locally advanced breast cancer (LABC) and palliative therapy of metastatic breast cancer (MBC) due to rising needs. METHODS: Analysis was performed from the public payers' perspective (National Health Fund) in Poland. Two scenarios were compared: present and future. Docetaxel is reimbursed in Poland for patients who fulfill special requirements (limited reimbursement). In the "present scenario" it was assumed that the number of patients is equal to the number of patients treated in 2007 year. In the "future scenario" it was assumed that the target population for docetaxel treatment will increase in the following years 2008-2012 due to better patient diagnosis and increase in disease incidence. for patients who fulfill special requirements (limited reimbursement). In the "present scenario" it was assumed that the number of patients is equal to the number of patients treated in 2007 year. In the "future scenario" it was assumed that the target population for docetaxel treatment will increase in the following years 2008-2012 due to better patient diagnosis and increase in disease incidence. Two scenarios were compared: present and future. Docetaxel is reimbursed in for patients who fulfill special requirements (limited reimbursement). In the "present scenario" it was assumed that the number of patients is equal to the number of patients treated in 2007 year. In the "future scenario" it was assumed that the target population for docetaxel treatment will increase in the following years 2008-2012 due to better patient diagnosis and increase in disease incidence. RESULTS: Estimated number of patients who will be treated (with restrictions) with docetaxel will increase from 2278 in 2008 to 2550 in 2012. Compared to 2007 total increase in number of patients will amount from 135 to 407 patients annually. Assuming continuation of docetaxel reimbursement in the treatment of LABC and MBC in years 2008-2012, the incremental expenses of the Public Payer to finance the treatment with docetaxel will amount 3,28 mln PLN in 2008 up to 11,23 mln PLN in 2012. Incremental QALYs will amount from 66 to 233 in 2008 and 2012 respectively. Incremental LYG will amount from 76 to 254 years in 2008 to 2012 respectively. CONCLUSIONS: Continuation of docetaxel reimbursement in the treatment of LABC and MBC will not considerably influence the expenses of the Public Payer in Poland. Treatment with docetaxel improves survival and functional outcomes compared with standard care. Discontinuation of the therapeutic program reimbursement would cause significant decrease of the total incremental effect among patients with locally advanced and metastatic breast cancer. . Treatment with docetaxel improves survival and functional outcomes compared with standard care. Discontinuation of the therapeutic program reimbursement would cause significant decrease of the total incremental effect among patients with locally advanced and metastatic breast cancer.
PCN14 A MODEL TO DEMONSTRATE THE COMPARATIVE COSTS BETWEEN PANITUMUMAB AND CETUXIMAB FOR THIRD-LINE METASTATIC COLORECTAL CANCER PATIENTS IN ITALY
Lamarque H 1 , Fitzgibbon JW 2 , Farrimond BJ 2 , Lavelle RJB 2 , Eggington SG 3 , Bracco A 1 1 AMGEN (Europe) GmbH, Zug, Switzerland, 2 IMS Consulting, Cambridge, Cambridgeshire, UK, 3 IMS Health, London, UK OBJECTIVES: To demonstrate the pharmacoeconomic savings provided by panitumumab (Vectibix®), a fully human anti-EGFR monoclonal antibody (mAB) when compared with cetuximab (Erbitux®), a chimeric mAB, based on practical usage considerations in metastatic colorectal cancer (mCRC) patients, from the Italian Payers' perspective. METHODS: The model demonstrated the annual savings provided by panitumumab versus cetuximab in a cohort of patients by grouping them into three distinct areas; low-weight patient savings, administration savings and safety savings. The products were compared based on dosing, administration and safety data from the product labels. Given the lower incidence of grade IV infusion reactions expected with panitumumab compared with cetuximab, safety savings were calculated by multiplying the comparative difference in frequency of infusion reactions by the Diagnosis-Related Group (DRG) for an anaphylactic shock. Administration savings compared the dosing schedules of panitumumab (biweekly) and cetuximab (weekly). Therapy visit costs were based on national tariffs (outpatient DRGs). For the average patient, with a weight of 73 kg and a surface area of 1.7 m 2 , panitumumab and cetuximab are priced at parity. However, over a range of patients, the average cost for panitumumab will be lower. The model used the normal distribution and the mean and standard deviations for weight and surface area, gained from an Italian retrospective patient survey, to define the cohort and calculate average savings Abstracts A463 over different combinations of patient weight and surface area. RESULTS: Savings of €3,404 per course per patient were shown; potentially saving the Italian health care system €7.67 million per year. This assumes that of the 2,252 third-line patients, 57% receive panitumumab and 43% receive Active Supportive Care in Year 1 based on the prevalence of the wild-type K-RAS mutation, compared with 100% receiving cetuximab. CONCLUSIONS: Results indicate that substantial savings are associated with panitumumab therapy over cetuximab therapy at national and perpatient levels.
PCN15 A COST-EFFECTIVENESS ANALYSIS OF IXABEPILONE FOR BREAST CANCER AT A TERTIARY CANCER CENTER
Lal LS, Maewal I, Miller LA, Smith WD, Arbuckle R University of Texas MD Anderson Cancer Center, Houston, TX, USA OBJECTIVES: This study evaluates the cost-effectiveness and the budget impact of ixabepilone, a new microtubule stabilizer for treatment of breast cancer, as part of the Formulary Management System at a major tertiary cancer center in the United States. METHODS: A decision analytical model was developed to estimate the incremental cost-effectiveness of ixabepilone for breast cancer, in patients who failed treatment with anthracycline and taxane. The model compared two strategies: combination therapy of ixabepilone with capecitabine compared to capecitabine alone. The outcome of interest was progression free life year (PFLY), based on published literature and clinical use estimates. Direct institutional medical costs for a one-year time period were utilized. One-way and two-way sensitivity analyses on the probabilities of disease progression were conducted. In addition, a budget impact analysis was also conducted for adding ixabepilone in the Formulary. RESULTS: Based on outcome estimates from literature and the application of the institutional costs, the cost per PFLY saved for ixabepilone for treatment of advanced breast cancer was $318,404. One-way sensitivity analysis on the efficacy probability (0-1.0) of the combination therapy indicated that ixabepilone's costeffectiveness ratios ranged from $205,000 to $1,190,000 per PFLY saved. Two-way sensitivity analysis with a willingness-topay threshold of $250,000 indicated that the majority of the time monotherapy is the more cost-effective option. Only if the probability of response to the combination is >30% and the probability of response to the monotherapy is <33%, does the combination therapy become more cost-effective. The budget impact model showed that the institution will utilize about $7.39 million worth of ixabepilone annually based on acquisition costs. CONCLUSIONS: Ixabepilone appears to be less cost-effective than other neoplastic agents for treatment of breast cancer. Future economic analyses will be conducted to determine how closely the current economic model predicts actual utilization and cost-effectiveness at the institution.
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ANALYSIS OF COSTS AND CONSEQUENCES IN CANCER PATIENTS RECEIVING CAPECITABINE
Roth S 1 , Lehmann S 1 , Simons S 1 , Dietrich ES 2 , Ko Y 3 , Kuhn W 4 , Ruberg K 5 , Schwindt P 6 , Wolter H 6 , Jaehde U 1 1 University of Bonn, Bonn, NRW, Germany, 2 TK Scientific Institute for Benefit and Efficiency in Health Care, Hamburg, Germany, 3 Johanniter Hospital, Bonn, NRW, Germany, 4 University Hospital Bonn, Bonn, NRW, Germany, 5 Kronen Apotheke Marxen, Wesseling, NRW, Germany, 6 Oncology Practice, Bonn, NRW, Germany OBJECTIVES: The purpose of this study was to analyse the disease-related costs as well as the side effect hand-foot syndrome (HFS) in oncologic patients receiving capecitabine. HFS is a dose and therapy limiting toxicity which is classified into severity grades 1 to 3. METHODS: Between April 2006 and August 2007 an observational study was conducted in Bonn, Germany on two oncologic outpatient wards and three oncologic practices. Breast and colorectal cancer patients starting oral chemotherapy with capecitabine were included and followed for six months. They rated their HFS at the end of each capecitabine cycle. The HFS grades were transformed into utility weights obtained from an earlier study in our group. From the perspective of the German statutory health insurance the direct disease-related costs (outpatient costs for pharmacotherapy, oncologist visits, diagnostics and inpatient costs) were assessed in a microcosting approach and referred to 2008. RESULTS: Thirty patients (16 breast, 14 colorectal cancer) were included. Their mean HFS severity grade was 1.1 (SD 0.7, median 1.0, range 0 to 2.75) corresponding to a mean utility weight of 0.88 (SD 0.14, median 0.92, range 1.00 to 0.44). Seven patients showed a HFS grade 3 (utility weight: 0.34) at least in one capecitabine cycle. On average €18,305 (80.4% outpatient, 19.6% inpatient) were calculated per breast cancer patient and €25,863 (71.2% outpatient, 28.8% inpatient) per colorectal cancer patient. Concerning the outpatient treatment, costs for pharmacotherapy represented the highest matter of expense (96.0% breast, 95.0% colorectal cancer). CONCLU-SIONS: In most patients HFS occurred in moderate severity. Nevertheless, 7 patients experienced HFS grade 3 affecting quality of life. Strategies to prevent this toxicity need to be developed. Especially costs for pharmacotherapy represent a cost-driving factor in this patient group indicating a need for strategies to optimize cost structure while containing or improving quality of treatment.
PCN17 ESTIMATING THE COST SAVINGS FROM THE INTRODUCTION OF KRAS TESTING IN THE MANAGEMENT OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS RECEIVING PANITUMUMAB IN GREECE
Papagianopoulou V 1 , Christodoulopoulou A 2 , Bracco A 3 , Yfantopoulos I 1 1 University of Athens, Athens, Greece, 2 Amgen Hellas, Athens, Greece, 3 Amgen (Europe) GmbH, Zug, Switzerland OBJECTIVES: Panitumumab is the first fully human anti-EGFR monoclonal antibody to be approved as monotherapy for patients with wild type (wt) KRAS mCRC after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. This novel treatment approach is the beginning of a new era of personalised treatment whereby KRAS status is evaluated and only patients who are likely to respond (wt KRAS) receive treatment. The objective of this study was to evaluate the overall budget impact (BI) of the use of panitumumab versus testing KRAS and treating patients with wt KRAS in Greece. METHODS: To consider overall costs associated with panitumumab treatment versus testing KRAS status and treating only wt KRAS patients with panitumumab, a decision analytic model was developed to evaluate BI. Primary drug costs, concomitant medications, infusion costs, radiation therapy, clinic visits, and hospitalisations were included in treatment costs. An expert panel was employed to map mCRC patient flow as a local cancer registry was not available. In this analysis, cost calculations for the public and private sectors were conducted separately. RESULTS: Out of 470 potentially eligible patients for panitumumab monotherapy, the decision analytic model targets 268 (57%) patients with wt KRAS, according to indication. Potential total cost of receiving panitumumab without taking KRAS status into consideration was €8.4 million in the public sector, while total cost including KRAS testing to all patients but
